In the latest market close, CRISPR Therapeutics AG (CRSP) reached $39.11, with a +1.48% movement compared to the previous day. This move lagged the S&P 500's daily gain of 2.03%. At the same time, the ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Plant breeding plays a vital role in ensuring global food security by increasing crop yields, improving nutritional quality ...

Methods: In this study, a novel diagnostic approach combining loop-mediated isothermal amplification (LAMP) with CRISPR-Cas12a technology was developed for detecting SP and MP in clinical respiratory ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

CRISPR–Cas, a bacterial defence system that recognizes and slashes specific sequences in viral genomes, gave scientists the power to delete or edit genes with remarkable precision. Developed in ...

In 2019, he raised $15 million in seed funding to use genetic technology such as CRISPR for work in conservation biology. After founding Colossal two years later, he garnered attention for ...

April 8, 2025 /PRNewswire/ -- Synthego and Vita Therapeutics, Inc. today announced a licensing agreement to integrate Synthego's high-fidelity hfCas12Max CRISPR system into Vita's cell therapeutic ...

The CRISPR Market had an estimated market share worth USD 3.4 billion in 2023, and it is predicted to reach a global market valuation of USD 17.8 billion by 2034, growing at a CAGR of 16.1% from 2024 ...